Lupin launches Luforbec 100/6 dose

24 Aug 2021 Evaluate

Lupin has launched Luforbec (beclometasone/formoterol) 100/6 dose pressurised metered dose inhaler (pMDI), making it available now to patients in the UK, with the potential to offer significant cost savings for the NHS.

Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 <50% predicted normal). Lupin is approved to manufacture Luforbec at its sites in Pithampur in India and Coral Springs in the US.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

1635.00 -52.75 (-3.13%)
14-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1545.25
Dr. Reddys Lab 5861.00
Cipla 1356.95
Zydus Lifesciences 984.75
Lupin 1635.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.